Zepbound vs Wegovy: Which Weight Loss Medication Works Better?

Zepbound and Wegovy are once-weekly injectable medications FDA-approved for chronic weight management in eligible patients. Both reduce appetite and support greater fullness, but they contain different active ingredients and act through different hormone pathways.

Zepbound contains tirzepatide, a dual GIP and GLP-1 receptor agonist. Wegovy contains semaglutide, a GLP-1 receptor agonist. Both can be highly effective when combined with an appropriate nutrition, activity, and follow-up plan.

Clinical Evidence

Clinical Evidence: Zepbound vs Wegovy

Separate pivotal trials and a direct head-to-head trial provide evidence about average weight-loss outcomes. Trial populations, methods, doses, and duration matter when interpreting the results.

SURMOUNT-5 Head-to-Head Trial

SURMOUNT-5 directly compared tirzepatide with semaglutide in adults with obesity but without diabetes. At 72 weeks, average body-weight change was approximately -20.2% with tirzepatide and -13.7% with semaglutide at the maximum tolerated doses used in the study.

This direct evidence supports greater average weight reduction with tirzepatide in the population studied. It does not guarantee that every patient will lose more weight with Zepbound.

SURMOUNT-1 and STEP 1

In SURMOUNT-1, tirzepatide produced average weight reductions of roughly 15% to 21% over 72 weeks depending on dose. In STEP 1, semaglutide 2.4 mg produced about 15% average weight reduction over 68 weeks.

Because these were separate trials, their results should not be treated as a direct comparison; SURMOUNT-5 provides the stronger comparative evidence.

Zepbound vs Wegovy at a Glance

Both medications are weekly injections approved for chronic weight management in eligible patients. Their active ingredients, receptor activity, dose schedules, and additional approved indications differ.

What Is Zepbound?

Zepbound contains tirzepatide, which activates both GIP and GLP-1 receptors. This dual action influences appetite, fullness, calorie intake, blood sugar, and metabolic health.

Zepbound is FDA-approved for chronic weight management in eligible patients and has an additional approved indication for moderate-to-severe obstructive sleep apnea in adults with obesity.

What Is Wegovy?

Wegovy contains semaglutide, a GLP-1 receptor agonist that supports fullness, reduces appetite, and slows gastric emptying.

Wegovy is FDA-approved for chronic weight management in eligible patients and to reduce certain major cardiovascular risks in qualifying adults with established cardiovascular disease and overweight or obesity.

Which Medication Produces More Weight Loss?

On average, tirzepatide produced greater weight reduction than semaglutide in the direct SURMOUNT-5 trial. Individual response can differ substantially, and the maximum tolerated dose, treatment adherence, side effects, and duration all influence outcomes.

Weight Loss Examples

The examples below show what 15% and 20% of starting body weight equal. They illustrate percentages and are not promised outcomes for either medication.

How Zepbound Works

Tirzepatide activates GIP and GLP-1 receptors. Researchers believe this dual mechanism contributes to appetite regulation, reduced calorie intake, weight loss, and metabolic improvements.

• Supports earlier fullness
• May reduce food cravings
• Helps lower calorie intake
• Influences glucose-dependent insulin response

How Wegovy Works

Semaglutide activates GLP-1 receptors. It reduces appetite, increases fullness, slows gastric emptying, and can help patients consume fewer calories.

• Increases satiety
• May reduce appetite
• Slows gastric emptying
• Supports lower calorie intake

Side Effects Comparison

Both medications commonly cause gastrointestinal symptoms, especially during dose escalation. Symptoms may improve with time, but patients should contact their care team about severe, persistent, or concerning effects.

Both labels include important warnings, contraindications, and a boxed warning concerning thyroid C-cell tumors. Product-specific prescribing information should be reviewed before treatment.

Which Medication Has Fewer Side Effects?

There is no universal answer. Dose-escalation speed, individual tolerance, diet, hydration, medical history, and other medications can affect tolerability. Some patients tolerate Wegovy better, while others tolerate Zepbound better.

Cost Comparison

Cash prices for both medications can be high. Actual out-of-pocket costs depend on pharmacy pricing, insurance benefits, deductibles, prior authorization, manufacturer savings eligibility, dose, and location.

Patients should verify live prices and coverage rather than relying on a fixed online estimate. The less expensive option varies from person to person.

Insurance Coverage Comparison

Coverage for either medication may require BMI documentation, qualifying conditions, medical-necessity review, prior authorization, or step therapy. A patient may meet medical eligibility criteria while still having no obesity-medication benefit.

Who May Qualify?

For chronic weight management, adults commonly qualify with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition. The products also have pediatric or additional indications with product-specific requirements.

Examples of relevant conditions can include high blood pressure, dyslipidemia, type 2 diabetes, sleep apnea, or cardiovascular disease. A licensed provider must confirm current label criteria and individual suitability.

Which Is Better for Diabetes?

Zepbound and Wegovy are not the brand products approved specifically for type 2 diabetes. Tirzepatide is marketed as Mounjaro for type 2 diabetes, while semaglutide is marketed as Ozempic for type 2 diabetes.

Patients with diabetes and obesity need an individualized plan that considers glucose control, weight goals, cardiovascular and kidney risk, medication duplication, and insurance coverage.

Patient Scenarios

These fictional examples illustrate how treatment discussions may differ. They are not predictions or prescribing recommendations.

Scenario 1: BMI 38 Without Diabetes

A patient weighing 250 pounds with a BMI of 38 may be eligible for either medication. Expected benefit, tolerability, coverage, and personal priorities help guide the decision.

Scenario 2: BMI 33 With Prediabetes

Both products may be considered after medical review. Insurance coverage and product-specific risks may become deciding factors.

Scenario 3: BMI 42 With Significant Weight-Loss Goals

A provider may discuss tirzepatide’s greater average weight loss in comparative evidence while also reviewing safety, access, sustainability, and the patient’s complete medical history.

Which Is the Best Weight Loss Medication?

Zepbound produced greater average weight loss in direct comparative evidence, while Wegovy remains highly effective and has extensive clinical evidence plus a distinct cardiovascular risk-reduction indication for qualifying adults.

The best medication is not determined by average weight loss alone. It should align with the patient’s medical history, approved indication, goals, tolerability, access, budget, and provider recommendations.

Key Zepbound vs Wegovy takeaways

• Zepbound contains tirzepatide and activates GIP and GLP-1 receptors.
• Wegovy contains semaglutide and activates GLP-1 receptors.
• Tirzepatide produced greater average weight loss than semaglutide in the direct SURMOUNT-5 trial population.
• Both medications can cause gastrointestinal side effects and have important warnings and contraindications.
• Coverage, affordability, safety, and individual treatment goals can matter as much as average trial results.

Frequently asked questions